Ever walked into a room and forgotten why, or misplaced your phone only to find it in your hand? These small cognitive glitches can become more noticeable with age. Add a cancer diagnosis to the mix, and concerns about memory and thinking can feel overwhelming. This complex interplay, explored in the video “Chemo Brain” in Older Adults: The Link Between Cancer & Cognitive Decline,” highlights a crucial aspect of geriatric oncology: Cancer-Related Cognitive Decline (CRCD).
The video emphasizes that cancer is largely a disease of aging, and both the disease itself and its treatments can accelerate aspects of aging, including in the brain. CRCD is an umbrella term for changes in memory, attention, executive functions, and processing speed that occur after a cancer diagnosis or treatment. These changes, even if subtle, can significantly impact quality of life and persist for months or even years.
A key point is that many older adults start their cancer journey with some pre-existing cognitive vulnerabilities, which the stress of cancer and its treatments can exacerbate. Identifying who is most at risk is paramount. Factors include age, lower “cognitive reserve” (your brain’s resilience built through education and stimulating activities), and frailty—a systemic loss of bodily reserve. Psychological factors like anxiety and depression, and symptom clusters like fatigue and poor sleep, also play a role. Researchers are even exploring biological markers, like certain genetic variations and indicators of “biologic age,” as well as visible changes in brain structure through neuroimaging.
Assessing cognitive function is vital, though often missed. National guidelines recommend screening all older adults with cancer before treatment. Brief tools like the MoCA or patient self-report questionnaires can help flag individuals who need a more in-depth evaluation.
Chemotherapy is frequently associated with “chemo brain” or “chemo fog,” with studies showing a significant increase in reported cognitive worsening and objective declines in memory and attention. While these changes are generally subtle compared to dementia, they can last for months or even years. Other treatments, such as androgen deprivation therapy (ADT) for prostate cancer, have been linked to an increased risk of dementia. Newer immunotherapies can also cause neurotoxicity, leading to cognitive disorders, though more research is needed specifically in older adults.
Managing CRCD is crucial for successful cancer treatment. Cognitive impairment can hinder a patient’s ability to manage medications, appointments, and report side effects, potentially impacting treatment outcomes and even survival. Providing adequate medical and social support, including caregiver burden monitoring, is essential. While there are no proven drug treatments for CRCD, behavioral interventions like cognitive rehabilitation and exercise programs show promise, though more research is needed specifically for older adults.
The future of CRCD research focuses on increasing older adult representation in studies, improving assessment tools, and developing tailored interventions that prioritize functional cognition and a patient’s overall quality of life. This holistic approach ensures that effective cancer treatment goes hand-in-hand with preserving cognitive health and independence, treating the whole person, not just the disease.